Morepen Laboratories

BSE: 500288 | NSE: MOREPENLAB | ISIN: INE083A01026 | SECTOR: Biotechnology & Drugs

49.80

-0.44 (-0.88%)
03 May 2024, 03:29 PM IST

Key Metrics

Influencer Count

-

Simple Moving Averages

DaysBSENSE

550.4750.52
1048.1948.21
2046.9747.01
5047.5047.51
10047.7447.75
30041.7741.77

News

Company Description

Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.

Company Officers